Since blockade of YAP1 in vitro plays a vital role in impairing the occurrence of CIS resistance, blocking YAP1 functions in vivo may have therapeutic benefits for cisplatin treatment-resistant tumors. Here, YAP1 is linked to in situ carcinoma.